Cite
HARVARD Citation
Ogata, A. et al. (2018). A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period. Modern rheumatology. 28 (1), pp. 76-84. [Online].